Ferrari Ludovica, Compagno Mirko, Campogiani Laura, Teti Elisabetta, Mulas Tiziana, Checchi Davide, Alessio Grazia, Caldara Federica, Coppola Luigi, De Simone Giuseppe, Ceccarelli Laura, Spalliera Ilaria, Vitale Pietro, Grelli Sandro, Andreoni Massimo, Sarmati Loredana, Iannetta Marco
Infectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, Italy.
Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Vaccines (Basel). 2022 Aug 2;10(8):1238. doi: 10.3390/vaccines10081238.
Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side effects and performed a nested case−control analysis comparing plasma levels of specific IgG titers between SARS-CoV-2-naïve and previously infected subjects after the first and the second vaccine doses. Results: After the first dose, SARS-CoV-2-naïve subjects experienced side effects more often than SARS-CoV-2 naïve subjects. Individuals with prior SARS-CoV-2 infection more often reported pain at the injection site, weakness, and fever than SARS-CoV-2-naïve subjects. After the second dose, the frequency of side effects was similar in the two groups. All subjects with prior SARS-CoV-2 infection developed either a high (>100 AU/mL) or intermediate (10−100 AU/mL) antibody titer. Among SARS-CoV-2-naïve subjects, the majority developed an intermediate titer. After the second dose, a high (>2000 AU/mL) antibody titer was more common among subjects with prior SARS-CoV-2 infection. Conclusions: vaccine-related side effects and a higher anti-SARS-CoV-2-RBD IgG titer were more common in subjects with previous infection than in SARS-CoV-2-naïve after the first, but not after the second dose of the BNT162b2 vaccine.
评估既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是否会影响接种BNT162b2疫苗后的副作用及特异性抗体产生。方法：我们纳入了1106名接种BNT162b2疫苗的医护人员。我们评估了既往SARS-CoV-2感染是否会影响副作用的数量和类型，并进行了巢式病例对照分析，比较初次和第二次接种疫苗后未感染SARS-CoV-2和既往感染过SARS-CoV-2的受试者血浆中特异性IgG滴度水平。结果：初次接种后，未感染SARS-CoV-2的受试者比感染过SARS-CoV-2的受试者更常出现副作用。既往感染过SARS-CoV-2的个体比未感染SARS-CoV-2的受试者更常报告注射部位疼痛、乏力和发热。第二次接种后，两组副作用的发生率相似。所有既往感染过SARS-CoV-2的受试者均产生了高（>100 AU/mL）或中（10-100 AU/mL）抗体滴度。在未感染SARS-CoV-2的受试者中，大多数产生了中滴度。第二次接种后，既往感染过SARS-CoV-2的受试者中高（>2000 AU/mL）抗体滴度更为常见。结论：在初次接种BNT162b2疫苗后，既往感染过的受试者比未感染SARS-CoV-2的受试者更常出现疫苗相关副作用和更高的抗SARS-CoV-2受体结合域（RBD）IgG滴度，但第二次接种后并非如此。
